A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs BAY 1125976 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 26 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.